CeriBell (NASDAQ:CBLL) Issues Earnings Results

CeriBell (NASDAQ:CBLL) released its quarterly earnings data on Tuesday. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04), FiscalAI reports. The firm had revenue of $29.34 million during the quarter, compared to analysts’ expectations of $29.18 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%.

Here are the key takeaways from CeriBell’s conference call:

• Q3 revenue rose 30% year over year to $29.3 million, supported by record additions of 35 hospitals and a total of 747 active accounts. Usage per account increased at a double-digit rate, driven by department expansion, provider engagement, and protocolization.
• The company launched its delirium monitoring solution commercially after a successful pilot that produced higher headband utilization and reported improvements in clinical decision-making. Management expects the offering to expand existing-account usage initially, although the rollout will be gradual and the product is being provided as a software upgrade without an incremental subscription fee.
• CeriBell received FDA 510(k) clearance for quantitative EEG trending and amplitude-integrated EEG analysis, with cloud-based releases planned for 2027. It also unveiled the Omni platform, which combines seizure, delirium, video, continuous monitoring, EKG compatibility, and additional EEG functionality, with a limited market release underway and a broader launch expected in 2027.
• Operating expenses increased 36% year over year to $46.9 million, contributing to a quarterly net loss of $21.4 million versus $13.5 million a year earlier. Adjusted EBITDA loss also widened to $12.1 million as the company continued investing in sales infrastructure, research and development, and new product launches.
• CeriBell raised the low end of its 2026 revenue outlook to $115 million-$117 million, representing 29%-31% growth, while maintaining the high end. The guidance excludes material contributions from neonatal, pediatric, and delirium products, which management expects to contribute more meaningfully in 2027; cash and marketable securities totaled $117.5 million at quarter-end.

CeriBell Stock Performance

Shares of CBLL opened at $28.27 on Wednesday. The company has a 50-day simple moving average of $25.06 and a two-hundred day simple moving average of $20.85. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The firm has a market capitalization of $1.09 billion, a PE ratio of -16.06 and a beta of 0.86. CeriBell has a one year low of $10.85 and a one year high of $28.89.

Insider Transactions at CeriBell

In other news, VP David Foehr sold 9,255 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $24.25, for a total value of $224,433.75. Following the completion of the transaction, the vice president owned 34,144 shares in the company, valued at $827,992. This trade represents a 21.33% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Xingjuan Chao sold 39,540 shares of CeriBell stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $24.61, for a total value of $973,079.40. Following the sale, the chief executive officer owned 767,191 shares in the company, valued at $18,880,570.51. This represents a 4.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 174,905 shares of company stock worth $4,312,995. 17.70% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. TD Cowen lifted their price objective on CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, October 2nd. Barclays upgraded CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 16th. BTIG Research reiterated a “buy” rating on shares of CeriBell in a report on Wednesday. Finally, Canaccord Genuity Group boosted their price objective on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.00.

Key Stories Impacting CeriBell

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: CeriBell announced the commercial launch of a delirium-monitoring solution, expanding its point-of-care brain-monitoring platform. The new offering could broaden the company’s product reach and growth opportunities. Article: Ceribell Expands Its Point-of-Care Brain Monitoring Platform
• Positive Sentiment: Third-quarter revenue was $29.34 million, slightly above analyst expectations of about $29.2 million. Article: Ceribell Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: Reports differed on quarterly loss per share: Zacks cited a $0.48 loss, better than its $0.50 consensus estimate, while another report gave a $0.55 loss versus a $0.51 estimate. The discrepancy makes the earnings signal less clear. Article: CeriBell Reports Q3 Loss, Tops Revenue Estimates
• Negative Sentiment: The MarketBeat report said EPS missed analyst expectations, and the loss widened from a year earlier, highlighting continued profitability challenges. Article: CeriBell quarterly earnings

CeriBell Company Profile

CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.

The company’s primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.